-
Mashup Score: 7Case Series Examining the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial - CROI Conference - 22 day(s) ago
Background: Long-acting antiretroviral therapy (LA-ART) is novel and has been used for both virologically-suppressed (VS) and viremic patients with adherence challenges. The currently-approved LA-ART combination – cabotegravir (CAB) and rilpivirine (RPV) – is limited by the relatively high prevalence (up to 10%) of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistant virus globally and is not endorsed
Source: www.croiconference.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 133
CROI leadership has continued to monitor the growing COVID-19 outbreak in the US and globally each day. Many countries, agencies, and institutions have now banned travel, and many infectious disease physicians are urgently needed to care for patients with COVID-19 in…
Source: www.croiconference.orgCategories: Healthcare ProfessionalsTweet
-
Mashup Score: 4
CROI leadership has continued to monitor the growing COVID-19 outbreak in the US and globally each day. Many countries, agencies, and institutions have now banned travel, and many infectious disease physicians are urgently needed to care for patients with COVID-19 in…
Source: www.croiconference.orgCategories: Infectious DiseaseTweet
-
Mashup Score: 5CROI Update for March 3, 2020 | CROI Conference - 4 year(s) ago
After careful deliberation and consideration of thoughtful input from coronavirus, infectious disease, and public health experts, and feedback from CROI Program Committee leaders and CROI registrants, we plan to proceed with CROI 2020 with the following additional…
Source: www.croiconference.orgCategories: Healthcare ProfessionalsTweet
-
Mashup Score: 2CROI Update for March 2, 2020 | CROI Conference - 4 year(s) ago
As the events of the past 72 hours have evolved, it is clear that in many countries and regions of the world, including here in the U.S., SARS CoV-2 has continued to spread. In a number of countries, again including the U.S., evidence has emerged that the virus is…
Source: www.croiconference.orgCategories: Healthcare ProfessionalsTweet
LENACAPAVIR/CABOTEGRAVIR: Our case series on using LEN/CAB in those with NNRTI resistance now in print at Open Forum Infectious Diseases. Next step is a trial in the ACTG https://t.co/vwaO2dQnim